Audentes Therapeutics — Technical Presentation (September 2017)
23 slides from Audentes Therapeutics's technical presentation, Sep 27, 2017
Slide 1: AT132 for X-Linked Myotubular Myopathy INCEPTUS Study Interim Results
AT132 for X-Linked Myotubular Myopathy INCEPTUS Study Interim Results Exhibit 99.3
Slide 2: Safe Harbor
CONFIDENTIAL Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that ma
Slide 3: XLMTM Overview: A Fatal Disease with no Treatment Options
Serious, life-threatening rare disease Significant impairment of respiratory and neuromuscular function Estimated 50% mortality by 18 months Incidence: 1 in 50K newborn males Monogenic, well-understood biology MTM1 gene encodes myotubularin, an enzyme required for normal development and function of
Slide 4: AT132 Clinical Development Program
AT132 Clinical Development Program INCEPTUS Prospective Natural History Run-in Study in XLMTM Patients N≈16 Longitudinal baseline and within-patient control for ASPIRO Facilitates enrollment in and operational aspects of ASPIRO ASPIRO A Phase 1/2 Gene Therapy Study in XLMTM Patients N=12 Assessment
Slide 5: INCEPTUS: Beginning...
AUDENTES > INCEPTUS: BEGINNING... Courageous Patients. Bold Effort.
Slide 6: INCEPTUS Study Overview
Objectives To characterize the natural history of children with XLMTM, with a specific focus on respiratory and neuromuscular measurements To assess the burden of disease in XLMTM subjects and caregivers INCEPTUS Study Overview Inclusion Criteria Subject is male < 4 yrs. old Genetically confirmed XL
Slide 7: INCEPTUS Clinical Study Sites
INCEPTUS Clinical Study Sites Plan to use same study sites in ASPIRO
Slide 8: INCEPTUS Enrollment and Follow-up Duration
INCEPTUS Enrollment and Follow-up Duration As of September 14, 2017 Note: Interim data as of September 14, 2017
Slide 9: INCEPTUS: Non-treatment Serious Adverse Events
23 Serious Adverse Events 89 Adverse Events 1 patient death High frequency of hospitalizations and life-threatening events due to respiratory tract infections Approximately 100 cumulative hospitalization days in patients with SAEs INCEPTUS: Non-treatment Serious Adverse Events High frequency of life
Slide 10: INCEPTUS Measures of Neuromuscular Function
INCEPTUS Measures of Neuromuscular function
Slide 11: Key Neuromuscular Function Measures
CHOP-INTEND Designed to assess motor function in congenital myopathies Used in non-ambulant children up to 3 years of age Assessments include: Spontaneous movement of upper and lower extremities Rolling elicited from legs and arms Head control Max score of 64 is reached in first 3-6 mos. in healthy
Slide 12: CHOP-INTEND Scores
CHOP-INTEND Scores All patients have severely impaired motor abilities and have missed all major gross motor milestones (rolling, standing, walking) Maximum score of 64 points normally reached in healthy children by 3 to 6 months of age Note: Interim data as of September 14, 2017 Age Range: 8 mos. t
Slide 13: MFM-20 Scores
MFM-20 Scores All patients scoring well below normal on neuromuscular function Normal score in healthy children over 2 years of age Note: Interim data as of September 14, 2017 Age Range: 8 mos. to 4 yrs.
Slide 14: INCEPTUS Respiratory function, strength, and endurance
INCEPTUS Respiratory function, strength, and endurance
Slide 15: Key Respiratory Function Measures
Key Respiratory Function Measures Ventilator dependence and settings Ventilator dependence over the previous 24 h Changes in ventilator settings (rate and pressure) Key measures: O2 saturation, CO2 levels, serum bicarbonate Respiratory sprinting test Time that patient is able to sustain effective re
Slide 16: Ventilator Dependence Within the Previous 24 Hours
Ventilator Dependence Within the Previous 24 Hours Majority of patients require continuous (24/7) ventilator support Invasive Ventilation N=13/18 Non-Invasive Respiratory Support (Bi-PAP) N=5/18 Note: Interim data as of September 14, 2017
Slide 17: Respiratory Sprinting Test – Median Time Off Ventilator
Respiratory Sprinting Test – Median Time Off Ventilator Most patients cannot tolerate more than 10 min off ventilator Note: Only patients on invasive ventilator support undergo a sprinting test Note: Interim data as of September 14, 2017
Slide 18: Maximum Inspiratory Pressures
Maximum Inspiratory Pressures Respiratory strength of patients as measured by maximum inspiratory pressure is consistently well below normal levels Normal minimal pressures in healthy children Note: Interim data as of September 14, 2017
Slide 19: ASPIRO: To Aspire...
AUDENTES > ASPIRO: TO ASPIRE... Courageous Patients. Bold Effort.
Slide 20: ASPIRO Phase 1/2 Clinical Study
ASPIRO Phase 1/2 Clinical Study Baseline AT132 Administration Subjects from INCEPTUS Weeks 1 – 4 Prednisolone Weeks 5–9 Taper Extension study Baseline Assessments Neuromuscular Respiratory Biopsy Assessments Neuromuscular Respiratory Biopsy Assessments Neuromuscular Respiratory Biopsy Assessments Ne
Slide 21: ASPIRO Phase 1/2 Clinical Study
ASPIRO Phase 1/2 Clinical Study Cohort #1 control Cohort #3 control Cohort #2 control All control subjects treated after optimal dose is determined Cohort #1: Patient 1 Cohort #1: Patients 2 & 3 Cohort #2: Patient 1 Cohort #2: Patient 2 & 3 Cohort #3: Patient 1 Cohort #3: Patients 2 & 3 Optimal dose
Slide 22: INCEPTUS Key Findings and Program Next Steps
INCEPTUS study of XLMTM key findings to date High frequency of life-threatening events Severely impaired neuromuscular motor development and function Permanent ventilator dependence in many patients Findings are generally consistent across age range under study Implications for ASPIRO Planned effica
Slide 23: AT132 for X-Linked Myotubular Myopathy INCEPTUS Study Interim Results
AT132 for X-Linked Myotubular Myopathy INCEPTUS Study Interim Results
Audentes Therapeutics — Technical Presentation (September 2017) on 6ix